组蛋白去乙酰化酶抑制剂在肿瘤研究中的机制及临床应用

Mechanisms and clinical applications of HDAC inhihitors in cancer

组蛋白去乙酰化酶（HDAC）介导的可逆性组蛋白乙酰化对一系列生理进程及恶性肿瘤的调控产生重要影响。由于HDAC抑制剂（HDACi）可以促进肿瘤细胞凋亡而对正常细胞作用极小，使其已经发展成为一类新型的抗肿瘤药物，其中部分已进入临床试验阶段。HDACi中如伏立诺他及罗米地辛已经被FDA批准用于进展期、复发难治的皮肤T细胞淋巴瘤患者中。对HDAC药物作用机制的研究将有助于其深入临床应用。

Acetylation regulated by histone deacetylases （HDAC） has a broad influence on plenty of physiological processes and regulation of malignant tumor. HDAC inhibitors can promote tumor cell apoptosis and have little effect on normal cells, so they have been developed a new kind of anti-tumor agent, and part of them have entered clinical trials. Vorinostat and romidepsin have been approved by FDA for treating cutaneous T cell lymphoma patients with progressive, persistent and recurrent disease. Studies of the molecular mecha- nisms of the HDAC inhibitors will contribute to the further clinical application.